MedTrace Logo

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

NCT05840016 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 532

Last updated 2025-05-02

No results posted yet for this study

Summary

This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with chemotherapy versus Tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC.

Conditions

  • Advanced Squamous Non Small Cell Lung Cancer

Interventions

DRUG

AK112, Carboplatin, Paxlitaxel

IV infusion,Specified dose on specified days

DRUG

Tislelizumab, Carboplatin, Paxlitaxel

IV infusion,Specified dose on specified days

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-17
Primary Completion
2025-02-28
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05840016 on ClinicalTrials.gov